Nathan J. Schauer

Nathan J. Schauer

Auto-generated profile, based on publicly available information

Nathan J. Schauer

Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2017 in Cell Chemical Biology
Verified
Journal Article
Closed access
ILIlaria Lamberto
Ilaria Lamberto
XLXiaoxi Liu
Xiaoxi Liu
HSHyuk-Soo Seo
Hyuk-Soo Seo
NSNathan J. Schauer
Nathan J. Schauer
RIRoxana E. Iacob
Roxana E. Iacob
SBSara J. Buhrlage
Sara J. Buhrlage

4 November 2019 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
NSNathan J. Schauer
Nathan J. Schauer
RMRobert S. Magin
Robert S. Magin
XLXiaoxi Liu
Xiaoxi Liu
LDLaura M. Doherty
Laura M. Doherty
SBSara J. Buhrlage
Sara J. Buhrlage

1 May 2019 in Cell Metabolism
Verified
Journal Article
Closed access
IHIsaac S. Harris
Isaac S. Harris
JEJennifer E. Endress
Jennifer E. Endress
JCJonathan L. Coloff
Jonathan L. Coloff
LSLaura M. Selfors
Laura M. Selfors
SMSamuel K. McBrayer
Samuel K. McBrayer
JBJoan Brigge
Joan Brigge

2 October 2017 in Nature Chemical Biology
Verified
Journal Article
Closed access
PDF file
Ellen WeisbergEllen Weisberg
Ellen Weisberg
NSNathan J Schauer
Nathan J Schauer
JYJing Yang
Jing Yang
ILIlaria Lamberto
Ilaria Lamberto
LDLaura Doherty
Laura Doherty
SBSara J Buhrlage
Sara J Buhrlage

24 March 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
NSNathan J. Schauer
Nathan J. Schauer
XLXiaoxi Liu
Xiaoxi Liu
RMRobert S. Magin
Robert S. Magin
LDLaura M. Doherty
Laura M. Doherty
WCWai Cheung Chan
Wai Cheung Chan
SBSara J. Buhrlage
Sara J. Buhrlage
Ubiquitin specific peptidase 7 (USP7) is a deubiquitinating enzyme (DUB) that removes ubiquitin tags from specific protein substrates in order to alter their degradation rate and sub-cellular localization. USP7 has been proposed as a therapeutic target in several cancers because it has many reported substrates with a role in cancer progression, including FOXO4, MDM2, N-Myc, and PTEN. The multi-substrate nature of USP7, combined with the modest potency and selectivity of early generation USP7 inhibitors, has presented a challenge in defining predictors of response to USP7 and potential patient populations that would benefit most from USP7-targeted drugs. Here, we describe the structure-guided development of XL177A, which irreversibly inhibits USP7 with sub-nM potency and selectivity across the human proteome. Evaluation of the cellular effects of XL177A reveals that selective USP7 inhibition suppresses cancer cell growth predominantly through a p53-dependent mechanism: XL177A specifically upregulates p53 transcriptional targets transcriptome-wide, hotspot mutations in TP53 but not any other genes predict response to XL177A across a panel of ~500 cancer cell lines, and TP53 knockout rescues XL177A-mediated growth suppression of TP53 wild-type (WT) cells. Together, these findings suggest TP53 mutational status as a biomarker for response to USP7 inhibition. We find that Ewing sarcoma and malignant rhabdoid tumor (MRT), two pediatric cancers that are sensitive to other p53-dependent cytotoxic drugs, also display increased sensitivity to XL177A.

25 July 2018 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
BSBjörn Stolte
Björn Stolte
AIAmanda Balboni Iniguez
Amanda Balboni Iniguez
NDNeekesh V. Dharia
Neekesh V. Dharia
ARAmanda L. Robichaud
Amanda L. Robichaud
ACAmy Saur Conway
Amy Saur Conway
KSKimberly Stegmaier
Kimberly Stegmaier
Ewing sarcoma is a pediatric cancer driven by EWS-ETS transcription factor fusion oncoproteins in an otherwise stable genomic background. The majority of tumors express wild-type TP53, and thus, therapies targeting the p53 pathway would benefit most patients. To discover targets specific for TP53 wild-type Ewing sarcoma, we used a genome-scale CRISPR-Cas9 screening approach and identified and validated MDM2, MDM4, USP7, and PPM1D as druggable dependencies. The stapled peptide inhibitor of MDM2 and MDM4, ATSP-7041, showed anti-tumor efficacy in vitro and in multiple mouse models. The USP7 inhibitor, P5091, and the Wip1/PPM1D inhibitor, GSK2830371, decreased the viability of Ewing sarcoma cells. The combination of ATSP-7041 with P5091, GSK2830371, and chemotherapeutic agents showed synergistic action on the p53 pathway. The effects of the inhibitors, including the specific USP7 inhibitor XL-188, were rescued by concurrent TP53 knockout, highlighting the essentiality of intact p53 for the observed cytotoxic activities. Graphical Abstract